Endothelium-Derived Engineered Extracellular Vesicles Protect the Pulmonary Endothelial Barrier in Acute Lung Injury

Quick Facts

• Publication title: Endothelium-Derived Engineered Extracellular Vesicles Protect the Pulmonary Endothelial Barrier in Acute Lung Injury
• Journal: Adv Sci
• Year: 2023
• DOI: 10.1002/advs.202306156
• PMID/PMCID: 38062916; PMC10853733

Research overview

Acute lung injury (ALI) is a severe respiratory disease with a high mortality rate. Taken together, these findings suggest that LET-EVs-miRNA-125b can treat ALI by protecting the endothelial barrier integrity.

Key findings

Acute lung injury (ALI) is a severe respiratory disease with a high mortality rate.

The integrity of the pulmonary endothelial barrier influences the development and prognosis of ALI.

Therefore, it has become an important target for ALI treatment.

Extracellular vesicles (EVs) are promising nanotherapeutic agents against ALI.

Echo Biotech Role

Echo Biotech contributed targeting-peptide/surface modification.

Related platforms: Echosome®

Related services and capabilities: Targeting Peptide / Surface Modification

References

Original publication: Endothelium-Derived Engineered Extracellular Vesicles Protect the Pulmonary Endothelial Barrier in Acute Lung Injury Advanced Science. 2023. DOI: 10.1002/advs.202306156. PMID/PMCID: 38062916; PMC10853733.